Skip to content

The 12 Reclassified Peptides

Long-form pillars for each of the twelve peptides removed from FDA Category 2 on April 15, 2026. Research base, legal status, expected pricing, and the legitimate sourcing path. Updated as the regulatory picture clarifies.

Short answer: twelve therapeutic peptides — BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, Epitalon, GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF — are compoundable by licensed 503A pharmacies under valid patient-specific prescriptions after the April 15, 2026 FDA reclassification. They are not FDA-approved, and gray-market research-chemical sales remain outside the legal supply chain. In July 2026, the FDA's compounding advisory committee recommended six of the twelve (BPC-157, TB-500, KPV, MOTS-c, epitalon, semax) for the 503A bulks list — a recommendation that still needs formal rulemaking. The incoming FDA commissioner — Trump nominated Dr. Heidi Overton on Aug 19 — inherits that decision, plus the undecided 503B GLP-1 exclusion. What the Overton nomination means for peptide compounding →

BPC-157
Recovery and tissue repair. Most-studied on the list.
TB-500
Tissue repair, often paired with BPC-157.
KPV
Gut and skin anti-inflammatory.
MOTS-c
Mitochondrial and longevity-oriented.
DSIP
Sleep architecture and stress.
Semax
Cognitive, with a Russian clinical history.
Epitalon
Longevity and telomere research.
GHK-Cu
Skin, hair, tissue. Most cosmetic evidence base.
Melanotan II
Pigmentation. The most controversial on the list.
LL-37
Immune and antimicrobial.
Dihexa
Cognitive nootropic. Strong preclinical, weak human data.
PEG-MGF
Muscle recovery. On the WADA prohibited list.